Last reviewed · How we verify
Flumist Quadrivalent Nasal Product
Flumist Quadrivalent Nasal Product, developed by the University of Alabama at Birmingham, is a marketed influenza vaccine with a key composition patent expiring in 2028. Its nasal administration offers a non-injectable alternative, which can be a significant competitive advantage in patient compliance and convenience. The primary risk is the lack of revenue data and key trial results, which may limit its market visibility and investor confidence.
At a glance
| Generic name | Flumist Quadrivalent Nasal Product |
|---|---|
| Also known as | live attenuated influenza vaccine |
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection (PHASE4)
- Maternal Flu Vaccine Trial in Bamako, Mali (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: